February 6, 2018 Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference
December 14, 2017 Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
December 11, 2017 Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
December 4, 2017 Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
November 14, 2017 Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
November 14, 2017 Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller
November 1, 2017 Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
October 31, 2017 Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain
October 11, 2017 Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma